Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Top-line data from the double-blind Phase II 022 trial showed that ipilimumab had dose-dependent effects. Patients received 0.3,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury